

the amendments.

The Response

The Examiner has required restriction to one of the following inventions pursuant to 35 U.S.C. §§121 and 372:

- I. Claims 1-9, drawn to an OKT3 monoclonal antibody characterized by an exchange of cysteine at H100A and methods of producing said antibody.
- II. Claim 10, drawn to a method of use of the cysteine exchanged antibody in eliminating transplant rejection.
- III. Claim 11, drawn to a method of use of the cysteine exchanged antibody in tumor diagnosis.
- IV. Claim 11, drawn to a method of use of the cysteine exchanged antibody in tumor treatment.


In response to the Restriction Requirement, Applicants hereby elect the invention of Group I, Claims 1-9. Applicants expressly reserve the right to prosecute claims directed to the remaining allegedly distinct groups in one or more continuing or divisional applications.

CONCLUSION

Applicants believe that the application is in good and proper condition for allowance. Early notification of allowance is earnestly solicited. If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is encouraged to call the undersigned at (650) 463-8109.

Respectfully submitted,

Date: March 6, 2001


Albert P. Halluin (Reg. No. 25,227)
Viola T. Kung (Reg. No. 41,131)

HOWREY SIMON ARNOLD & WHITE, LLP
301 Ravenswood Avenue
Box 34
Menlo Park, CA 94025
(650) 463-8109